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Abstract
Background: Toxoplasma gondii is an obligate intracellular zoonotic parasite of the phylum Apicomplexa which
infects a wide range of warm-blooded animals, including humans. In this study in-vivo induced antigens of this
parasite was investigated using in-vivo induced antigen technology (IVIAT) and pooled sera from patients with
serological evidence of acute infection.
Methods: The pooled sera was first pre-absorbed against three different preparations of antigens from in-vitro-
grown cells of each T. gondii and E. coli XL1-Blue MRF’, subsequently it was used to screen T. gondii cDNA phage
expression library. Positive clones from each group were subjected to quantitative real-time PCR expression analysis
on mRNA of in-vivo and in-vitro grown parasites.
Results: A total of 29 reactive clones from each IgM and IgG immunoscreenings were found to have high
homology to T. gondii genes. Quantitative real-time PCR expression analysis showed that 20 IgM-detected genes
and 11 IgG-detected genes were up-regulated in-vivo relative to their expression levels in-vitro. These included
genes encoding micronemes, sterol-regulatory element binding protein site, SRS34A, MIC2-associated protein
M2AP, nucleoredoxin, protein phosphatase 2C and several hypothetical proteins. A hypothetical protein (GenBank
accession no. 7899266) detected by IgG had the highest in-vivo over in-vitro fold change of 499.86; while another
up-regulated hypothetical protein (GenBank accession no. 7898829) recognized by IgM showed high sensitivity
(90%) and moderate specificity (70%) in detecting T. gondii antibodies when tested with 20 individual serum
samples.
Conclusion: The highly up-regulated genes and the corresponding proteins, in particular the hypothetical proteins,
may be useful in further studies on understanding the disease pathogenesis and as potential vaccine candidates.
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Background
Toxoplasmosis is caused by the zoonotic and ubiquitous
Toxoplasma gondii, with up to 30% of the world human
population affected by this parasite. Infection usually oc-
curs by ingestion of T. gondii oocysts from infected cats
or consumption of undercooked meat containing the
parasite cysts. Environmental, cultural factors and eating
habits are thought to be contributing factors in the
transmission of this infection [1-4]. The foetus of an
infected mother can acquire this infection by vertical
transmission through the placenta during early preg-
nancy. In congenital toxoplasmosis most of the mothers
and newborns are asymptomatic but severe sequelae
may develop later in the infant life such as inflammatory
lesions, mental retardation, seizures and choriorentitis
with or without hydrocephaly. Prompt treatment of the
affected child would be possible if diagnosed early [5-8].
Diagnosis of toxoplasmosis is usually performed by de-
tection of IgG and IgM against T. gondii. In addition,
IgG avidity test is an important additional test that is
routinely performed; with low IgG avidity suggesting
acute infection while high IgG avidity confirms chronic
infection [9].
In-vivo induced antigen technology (IVIAT) is a new
and promising method introduced by Martin Handfield
et al. in 2000 which can be used to determine in-vivo in-
duced antigens that are directly related to the human in-
fection and thus reduce false-positive results caused by
the differences between proteins expressed during in-
vitro culture and actual human infection [10]. IVIAT
uses sera from patients or animals infected with the
pathogen of interest and therefore obviate the need for
animal models. Up-regulation of identified genes by
IVIAT can be assessed by techniques such as quantita-
tive real time PCR (RT-PCR) or microarray [10-12]. In a
previous study, our group has used IVIAT to identify in-
vivo induced genes of T. gondii which expresses proteins
reactive with Toxoplasma specific IgG antibodies in
chronically-infected individuals [13].
In the present study we applied IVIAT to identify in-vivo
induced antigens of T. gondii using sera of acutely-
infected patients with low anti-Toxoplasma IgG avidity
and high IgM positivity. These antigens may be potentially
useful as diagnostic markers, vaccine candidates or in in-
creasing our understanding of the disease pathogenesis.
Methods
Parasite strain and growth conditions
In-vitro culture of T. gondii RH strain in Vero cells was
performed under conditions previously optimized in our
laboratory [14]. Vero cells were washed four times at
85% confluence with phosphate buffered saline (PBS),
followed by addition of DMEM medium (Gibco BRL,
USA) containing 100 μg/ml streptomycin and 100 IU/ml
penicillin (Gibco BRL, USA) with 10% (v/v) fetal bovine
serum (Invitrogen, USA). Subsequently the cells were
seeded with 1x107 T. gondii tachyzoites harvested from
infected mice. After 3–4 days the maximum release of
tachyzoites was observed and the culture containing par-
asites was centrifuged and the pelleted tachyzoites was
kept at −80°C.
To produce in-vivo grown tachyzoites, Swiss albino mice
were intraperitoneally infected with 1 × 103 tachyzoites
of T. gondii RH strain. After three to four days post-
infection, the peritoneal cavity fluid was aseptically
harvested with 5 ml of RPMI-1640 medium containing
penicillin streptomycin (RPMI-PS), pH 7.2 (Gibco®, Life
Technologies, USA). The supernatant containing tachy-
zoites was collected, centrifuged, washed with PBS and
pelleted tachyzoites immediately kept at −80°C for RNA
extraction. Approval from the USM Animal Research Eth-
ics Committee was obtained prior to performing the ani-
mal infection.
Serum samples
Commercial IgM and IgG ELISA kits (Euroimmun,
Germany) were used to determine the Toxoplasma ser-
ology status of the serum samples in this study. Twelve
sera samples were obtained from patients with clinical evi-
dence of toxoplasmosis. Toxoplasma serology performed
on the serum samples showed high IgM antibody levels
and low IgG avidity indices. These sera were collected by
one of the co-authors from Molecular Parasitology La-
boratory, Parasitology Department, Pasteur Institute of
Iran. Ethical clearance from the institution and informed
consents from patients were obtained. Prior to performing
IVIAT, equal volume of each serum samples was pooled.
Out of a total of 12 serum samples, 10 were individually
used to determine sensitivity of selected clones. In
addition, another 10 serum samples from healthy individ-
uals which were negative for both anti-Toxoplasma IgM
and IgG antibody were individually used to determine spe-
cificity of selected clones.
Sera pre-adsorption
Sera adsorption was performed according to previously
reported protocol with some slight modifications in
order to increase efficiency of the process so as to ‘com-
pletely’ remove in-vitro antigens [13,15]. One modifica-
tion was to increase the incubation of pooled sera with
each of cell pellet, heat denatured and non-heat-dena-
tured cell lysates of T. gondii & E. coli XL1-Blue MRF’
from 1 h to overnight at 4°C on a shaker. Each step was
repeated twice and thimerosol (1%) was added in order
to prevent contamination. Serum samples used for sensi-
tivity and specificity determination (section 2.8) were
preadsorbed with pellet, heat denatured and non-heat-
denatured cell lysates of only E. coli XL1-Blue MRF’.
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The efficiency of sera adsorption at each step was
checked using indirect enzyme-linked immunosorbent
assay (ELISA) according to the previously optimized
protocol [13]. The final adsorbed sera sample was
centrifuged and kept at −80°C.
T. gondii expression library
Custom-made T. gondii cDNA expression library was
constructed in Lambda ZAP® II system (Strategene,
USA) using mRNA from in-vitro grown T. gondii pellet.
The previously optimized dilution of cDNA library
immunoscreening was 103 for primary screening which
produces around 500–1000 plaques per plate. For sec-
ondary and tertiary screening 104 and 105 dilutions of
cDNA library were used respectively.
cDNA library immunoscreening
For T. gondii cDNA library screening a modified version
of a previously reported method was used [16]. For pri-
mary screening, the 103 dilution of cDNA library was
mixed with 600 μl of E. coli XL1-Blue MRF’ cells at
OD600nm 0.5, then plated on LB agar plates 3–4 h in a
42°C incubator until the plaques became visible. On the
next day, the agar plates were overlaid with nitrocellu-
lose filter disc pre-saturated with 10 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and incubated overnight
at 28°C. The filters were then removed from the plates,
washed (colony side up) with PBS-Tween 20, blocked
with 1:5 dilution of Super Block solution (Thermo Sci-
entific, USA) and incubated overnight with adsorbed
pooled serum at dilution 1:100. Subsequently after three
step of washing with PBS-Tween 20 the filters were in-
cubated with peroxidase-anti-human IgG (Invitrogen,
USA) at 1:3000 dilution or peroxidase-anti-human IgM
(Invitrogen, USA) at 1:2000 dilution for 1 h, washed and
then developed using chemiluminescence substrate
(Roche Diagnostics, Germany). The phage plaques on the
agar plates which corresponded to positive plaque images
on the X-ray film were cored out and subjected to second-
ary and tertiary screenings using the same serum. For sec-
ondary and tertiary screenings, higher dilutions were used
to produce much lower density plaques (<50 per plate)
with many isolated clones. Final positive clones were iso-
lated and placed in 500 μl SM buffer containing 3%
chloroform overnight at 4°C. Part of them were used dir-
ectly for in-vivo excision, while the rest were centrifuged
and the supernatant placed in 500 μl SM buffer with 7%
DMSO for long-term storage at −80°C.
In-vivo excision and plasmid purification
In-vivo excision was performed to convert the recombin-
ant phages to recombinant plasmids. The selected phage
clone (in 250 μl SM buffer) and 1 μl ExAssist helper
phage (>106 pfu/ml) (Stratagene, USA) was added to
200 μl of E. coli XL1-Blue MRF’ cells at OD450nm 1.0.
The culture was incubated at 37°C for 15 min followed
by addition of 3 ml of LB broth and incubation in 65°C
for 20 min. After centrifugation 10 μl of supernatant (ex-
cised phagemids) was mixed with 200 μl of SOLR cells
(Stratagene, USA) at OD 1.0 (405 nm) and plated over-
night at 37°C on LB ampicillin agar plate. Plasmids from
each sample was purified using commercial plasmid
preparation kit (Promega, USA) and sent for sequencing
using M13 forward and reverse primers. The sequences
identified by IVIAT in current study after sequencing
were then analyzed using GenBank and ToxoDB (http://
toxodb.org/toxo) databases. ToxoDB, a functional gen-
omic database for T. gondii which incorporates sequence
and annotation data, is integrated with other genomic-
scale data, including community annotation; expressed
sequence tags (ESTs) and gene expression data [17].
Quantitative real-time PCR analysis
The forward and reverse primers for each of the sequences
were designed using Primer Express 2.0 software (Applied
Biosystems, USA). Table 1 shows the primers designed
based on sequences of IgM-detected genes; while Table 2
shows the primers designed based on sequences of IgG-
detected genes. Pooled in-vitro-grown tachyzoites from 20
culture flasks (75 cm2) (Nunclon, Roskilde, Denmark) and
pooled in-vivo-grown tachyzoites from 35 mice were pre-
pared as described above. Total RNA was extracted and
purified using RNAeasy mini kit (Qiagen, Germany). The
DNase-treated RNA samples were converted to cDNA
using High Capacity cDNA Reverse Transcription Kits
(Applied Biosystems, USA). Real-time PCR was performed
using Quanti FastTect SYBR Green PCR Kit (Qiagen,
Germany) in a Rotor Gene 6000 Multiplex System
(Corbett Research, Australia). Each of the reaction mix
comprised 5 μl of cDNA (200 to 400 ng), 200 pmol of
each primer (forward and reverse) and 12.5 μl of 2× SYBR
Green mix and sufficient amount of dH2O to bring the
volume to 25 μl. The parameters for thermocycler were as
follow: 95°C for 5 min short hot-start, followed by 40 cycles
of 95°C for 10 sec for denaturing and subsequently com-
bine annealing/extension at 60°C for 30 sec. At the final
step of real-time PCR, melting curves with 1°C tem-
perature increments from 72°C to 95°C were incorporated.
Data analysis was performed using Rotor Gene 6000 Series
Software 1.7. First the expression level was normalized to
the reference β-actin gene as housekeeping gene. Next the
fold change of in-vivo expression of the gene relative to its
in-vitro expression level was calculated using 2-ΔΔCt
method [18].
Sensitivity and specificity determination
To determine the sensitivity and specificity of selected clones,
one clone was plated per petri dish and immunoscreening
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was performed as above with the exception that individual
serum samples from acutely infected patients were used
instead of pooled sera. Each nitrocellulose membrane was
divided into six sections i.e. for six different serum sam-
ples. Positive and negative controls were included in each
experiment. Sensitivity refers to the number of serum
samples from acute-infected individuals (n = 10) which
were reactive with the protein expressed by a particular
clone. Thus if 8 serum samples are reactive out of 10, the
sensitivity of the clone in the detection of anti-Toxo-
plasma antibodies in that group of serum samples is 8/10
or 80%. Specificity refers to the number of serum samples
from healthy individuals (n = 10) which were not reactive
with the protein expressed by a particular clone. Thus if 9
serum samples are not reactive out of the 10, the specifi-
city of the clone in the detection of anti-Toxoplasma anti-
bodies is 9/10 or 90%.
Results
Adsorption of pooled sera from patients with acute
toxoplasmosis
Figures 1A and 1B show that the pooled sera were ex-
haustively pre-adsorbed against T. gondii and E. coli
XL1-Blue MRF’ in-vitro antigens. Most of the reductions
in OD values were observed after pre-adsorption with
the pellet of the organisms. After the last step of serum
pre-adsorption, the OD values of 0.001-0.009 were
Table 1 Primers used in real-time PCR analysis of T.gondii











7898829 F 5′- CAATGTTTCGGGCAGCTCAT -3′
R 5′- GCTGTACTGAAACCGTCGATGTAG -3′
7894091 F 5′- CCACTCAAGCAGTTCCTGAAGA -3′
R 5′- GATCTCCGCGAAATCTGTCTCT -3′
7900912 F 5′- CGCATTTACAAGCGCCTGAT -3′
R 5′- TTCCACGCCTCGTTTACATG -3′
7899945 F 5′- CTTCTCGACGACATGCATCTG -3′
R 5′- TGGACGCACTGGATGTTCTG -3′
7893976 F 5′- AGCGCAGCAAGAACCAAGA -3′
R 5′- TTCCTCAAGAAGGCCATGGA -3′
7893824 F 5′- CTCACGTACGAGGCTAGATCCA -3′
R 5′- GTCCGCCAGGGCATTCTATT -3′
7899621 F 5′- AGGCACAGGCTCCACCATAC -3′
R 5′- AGCTCCAGGACGCGTAAGAG -3′
7901413 F 5′- TCTGAAGCTGCAAGGTTCCA -3′
R 5′- TTGCAGAGTAGGCTCGTCAAAC -3′
7894150 F 5′- TCCTCGAACGGCAGAGAAA -3′
R 5′- CCCCTCAGGTGTGAAGACATCT -3′
7895338 F 5′- AGAGCCGGTAGCACTGTGTTC -3′
R 5′- CGGTAACCCGGTGGACTTCT -3′
7898197 F 5′- GGATTTCGGCACGCTCAAT -3′















7899034 F 5′-CCTGGAACGTCCTTTCTGGAT -3′
Table 1 Primers used in real-time PCR analysis of T.gondii




















*F forward, R reverse.
**β-Actin was used as the housekeeping gene.
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observed for serum diluted 1:100, which was the dilution
used in the immunoscreening step.
cDNA library tittering, screening and clone isolation
Approximately 10 000 and 14 000 clones from T.gondii
recombinant phage cDNA library were screened with
HRP-conjugated anti-human IgM and IgG respectively. A
total of 35 clones were randomly selected from about 200
positive clones after the three stage immunoscreenings
(primary, secondary and tertiary) with anti-human IgM-
HRP. After sequencing, 29 clones showed high homology
(80-100 %) to T. gondii genes (Table 3). Meanwhile a total
of 38 clones were randomly selected from about 300 posi-
tive clones after the three stage immunoscreenings with
anti-human IgG-HRP. After sequencing, 29 clones showed
high homology (80-100%) to T. gondii genes (Table 4).
Assessment of IVIAT-identified gene expression by real-
time PCR
Due to the large number of samples in this study and
the use of different control samples for each round of
experiments, the detailed data could not be placed in
one table. Therefore only the fold changes of the exam-
ined sequences are presented in Tables 5 and 6 to show
the relative expression levels between in-vivo and in-
vitro grown parasites for IgM-detected sequences and
IgG-detected sequences respectively. Of the 29 IgM-
detected genes analyzed, 20 (69%) were up-regulated in-
Table 2 Primers used in real-time PCR analysis of T.gondii
IVIAT identified genes by IgG










































7901507 F 5′-CGTATTCAAGCGCTGTTCGA -3′
R 5′-GAGACGATTGGCAGCGAATT -3′
Table 2 Primers used in real-time PCR analysis of T.gondii



















*F forward, R reverse.
**β-Actin was used as the housekeeping gene.
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vivo relative to their in-vitro expression levels with fold
changes between 3.11 and 330.8 (Figure 2A). Table 5
shows the fold changes of the expression of the genes;
the results indicated that there were significant in-
creases, ranging from 3.11 to 330.8-folds of the gene ex-
pression levels of in-vivo over in-vitro grown parasites
for 20 of 28 IgM-detected genes. Of the 29 IgG-detected
genes analyzed, 10 (34%) were up-regulated in-vivo rela-
tive to their expression levels in-vitro with fold changes
between 1.59 and 499.86 (Figure 2B). Table 6 shows the
fold changes of the expression of the genes; the results
indicated that there were significant increases, ranging
from 1.31 to 449.86-folds of the expression levels of in-
vivo over in-vitro for 11 of 29 IgG-detected genes.
Sensitivity and specificity evaluation
The top three most up-regulated IgM- and IgG-detected
clones were subjected to sensitivity and specificity ana-
lysis. Figure 3 shows an example of the immunoblot re-
sults, and Table 7 shows the summary of the results.
High sensitivity (90.0%) was observed for three IgM-
detected clones and one of the IgG-detected clones.
However the specificity was generally not high, the best
was a moderate specificity of 70% from a hypothetical
protein expressed by an IgM-detected clone (GenBank
accession no. 7898829).
Discussion
IVIAT has been applied in the study of several patho-
genic microorganisms based on the assumption that
conventional genetic and biochemical in-vitro ap-
proaches cannot mimic the real complex and dynamic
in-vivo situation of human infection [19-28]. In our re-
cent published report, T.gondii genes preferentially
expressed in-vivo were identified via immunoscreening
of T.gondii expression library with sera from chronically-
infected individuals followed by real time PCR to con-
firm the up-regulation of the identified genes. There
were increased expression levels of RNA of three genes
i.e. SRS3 and two hypothetical protein genes from in-
vivo grown T.gondii relative to the same genes from in-
vitro grown parasite [13]. This approach does not reflect
all of the antigens that are produced in-vivo by the
eukaryotic parasite, considering that a prokaryotic ex-
pression system was used in constructing the cDNA li-
brary. Nevertheless, this approach would be expected to
identify some of the in-vivo induced antigens of the
parasite [13].
The rationale for use of in-vitro instead of in-vivo
grown T. gondii has been explained in our previous re-
port [13]. A large quantity of ‘clean tachyzoites’ was
needed to make a good high titre T. gondii cDNA li-
brary. As compared to the use of mice as host, the in-
vitro method had less contamination and produced
higher quantity of parasites in a shorter period of time.
Although all the RNA may not be exactly the same be-
tween in-vivo and in vitro grown parasites, there should
be substantial similarities between them to enable us to
observe difference in expression levels between them.
Moreover IVIAT was introduced in order to reduce the
need to use animals. There are also many other IVIAT stud-
ies which used in-vitro grown organisms [16,20,29,30]. For
the same reasons (i.e. better purity and yield), we used T.
gondii RH strain instead of ME49 strain, although the
available genome information was derived from the latter.
The main serological marker for the diagnosis of acute
toxoplasmosis is specific IgM antibody, along with IgG
antibody of low avidity [31]. In the present study 29 T.
gondii sequences were detected by each IgM and IgG
secondary antibodies using sera from individuals with
serological evidence of acute infection. Due to resource
constraints, we did not endeavour to identify all of the
IVIAT-detected clones using a high-throughput method-
ology. However the random selection of the clones for
expression analysis by real-time PCR hopefully will pro-
vide a ‘snapshot’ of the in-vivo induced antigens of T.
gondii. The results of the transcriptional profiling sug-
gested the induction of genes that have been described
Figure 1 Optical densities (OD) of pooled serum adsorped by E.
coli and T. gondii. (A) serum adsorped by three different forms of E.
coli XL1-Blue MRF’, and (B) serum adsorped by three different forms
of T. gondii. 1-pooled non-preabsorped serum (control); 2-serum
adsorped by whole cell; 3-serum adsorped by non-heat denatured
cell lysate; and 4-serum adsorped by heat denatured cell lysate.
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as involved in parasite invasion and motility, cellular me-
tabolism, as well as other unknown functions. It is not-
able that the percentage of up-regulated genes among
the IgM-identified clones were twice the percentage of
up-regulated genes among the IgG-identified clones. It
is also interesting to note that among the IgM and IgG-
detected proteins, most were hypothetical proteins
namely 14 of 29 and 16 of 29 respectively. Limited sen-
sitivity and specificity evaluation of the top three most
up-regulated IgM- and IgG-detected clones showed
that none had good specificity, thus further testing with
more serum samples were not performed.





Gene name Description Homology
percentage
1 7895406 TGME49_026460 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 99%
2 7898829 TGME49_057020 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 86%
3 7894091 TGME49_030160 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 97%
4 7900912 TGME49_066920 phosphodiesterase Toxoplasma gondii ME49 phosphodiesterase, putative, mRNA 97%
5 7899945 TGME49_023050 40s ribosomal protein S20 Toxoplasma gondii ME49 40s ribosomal protein S20, putative 99%
6 7893976 TGME49_046620 G10 protein Toxoplasma gondiiME49 G10 protein, putative 99%
7 7893824 TGME49_066140 sterol-regulatory element
binding protein site
Toxoplasma gondii ME49 sterol-regulatory element binding
protein site 2 protease, putative, mRNA
83%
8 7899621 TGME49_060190 microneme protein Toxoplasma gondiiME49 95%
Toxoplasma gondii strain RH microneme protein 13 (MIC13)
gene, complete cds
9 7901413 TGME49_004530 microneme protein Toxoplasma gondii ME49 microneme protein TgMIC11 precursor
(MIC11) mRNA, complete cds
80%
10 7894150 TGME49_001880 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 81%
11 7895338 TGME49_071740 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 80%
12 7898197 TGME49_086550 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 81%
13 7895974 TGME49_048600 aspartate aminotransferase Toxoplasma gondii ME49 aspartate aminotransferase, putative,
mRNA
91%
14 7900011 TGME49_093510 poly(ADP)-ribose polymerase
domain-containing
Toxoplasma gondiiME49 poly(ADP)-ribose polymerase domain-
containing
99%
15 L06091.1 TOXGRA5A dense granule precursor
(GRA5) gene





TGME49_008440 cytoplasmic protein Cyt16 Toxoplasma gondii RH genomic DNA chromosome Ib,
cytoplasmic protein Cyt16 (cyt16) gene, complete cds
93%
17 7894239 TGME49_054870 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 89%
18 7896580 TGME49_008830 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 91%
19 7899034 TGME49_057360 Hypothetical protein Toxoplasma gondiiME49 hypothetical protein 99%
20 7899034 TGME49_057360 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 99%
21 AY707938.1 TGME49_071050 SRS34A (= SAG2A, P22) Toxoplasma gondii ME49 surface antigen P22 3′ flanking
sequence
100%
22 7894324 TGME49_030180 hypothetical protein Toxoplasma gondii ME49 hypothetical protein 98%
23 AF364813.1 TGME49_014940 MIC2-associated protein
M2AP
Toxoplasma gondii ME49 MIC2-associated protein precursor,
gene, complete cds
99%
24 7900910 TGME49_066900 cyclin, N-terminal domain-
containing protein
Toxoplasma gondiiME49 cyclin, N-terminal domain-containing
protein, mRNA
100%
25 7895521 TGME49_058470 Hypothetical protein Toxoplasma gondiiME49 hypothetical protein 99%
26 AM055943.1
7896316
TGME49_008440 hypothetical protein Toxoplasma gondii RH genomic DNA chromosome Ib 98%
27 7897539 TGME49_116540 Hypothetical protein Toxoplasma gondiiME49 hypothetical protein 97%
28 7895127 TGME49_027280 dense granule protein 3 Toxoplasma gondii ME49 dense granule protein 3, mRNA 90%
29 AM055943.1
7896796
TGME49_121620 dynamic-like protein Toxoplasma gondii RH genomic DNA chromosome Ib 96%
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Three different microneme proteins namely MIC6,
MIC11, MIC13 and a MIC2 associated protein were
identified in this study. MIC6 showed no difference in
the mRNA expression levels in-vivo over in-vitro, but
the other three genes detected by IgM (MIC11, MIC13
and MIC2 associated protein) showed significant in-
creases of mRNA expression level of in-vivo grown T.
gondii in comparison to in-vitro grown T. gondii.
Micronemes are sub-cellular organelles that belong to
apicomplexan protozoans which secrete proteins (MICs)
known to be responsible for the gliding motility and
subsequent invasion process of T. gondii [32]. MIC11 is
a conserved microneme protein in apicomplexan proto-
zoans that is secreted in a calcium dependent manner
while MIC13 has been reported as a successful vaccine
candidate against chronic infection and congenital
toxoplasmosis in mice [33,34]. In this study, the in-
creased expression levels of MIC11, MIC13 and a
MIC2 associated protein mRNA observed in the in-vivo
grown tachyzoites may be due to their role in attach-
ment and invasion of the tachyzoites in the host during
acute infection.





Gene name Description Homology
percentage
1 7901108 TGME49_069250 26S proteasome
regulatory subunit
Toxoplasma gondii ME49 26S proteasome regulatory subunit, putative 95%
2 7901478 TGME49_097940 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 99%
3 7894322 TGME49_030160 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 93%
4 7894761 TGME49_061750 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 98%
5 7897485 TGME49_005180 U1 small nuclear
ribonucleoprotein
Toxoplasma gondii ME49 U1 small nuclear ribonucleoprotein, putative 95%
6 7899395 TGME49_037230 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 80%
7 7895435 TGME49_024460 aminopeptidase N Toxoplasma gondii ME49 aminopeptidase N, putative 82%
8 7895096 TGME49_027910 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 95%
9 7895077 TGME49_025560 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 99%
10 7897605 TGME49_025080 40S ribosomal
protein S18
Toxoplasma gondii ME49 40S ribosomal protein S18, putative 84%
11 7899217 TGME49_068830 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 94%
12 AM055942.3 TGME49_095420 hypothetical protein Toxoplasma gondii RH genomic DNA chromosome Ia 87%
13 7894058 TGME49_002840 zinc finger (C3HC4
type)
Toxoplasma gondii ME49 zinc finger (C3HC4 type)/FHA domain-
containing protein
97%
14 7893896 TGME49_075310 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 94%
15 7899266 TGME49_047530 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 96%
16 7893521 TGME49_018520 protein MIC6 Toxoplasma gondii micronemal protein MIC6 (MIC6) mRNA, complete 95%
17 7893531 TGME49_018720 protein kinase Toxoplasma gondii ME49 calcium-dependent protein kinase, putative 91%
18 7896164 TGME49_025060 nucleoredoxin Toxoplasma gondii ME49 nucleoredoxin, putativ 98%
19 7896097 TGME49_026520 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 98%
20 7901507 TGME49_078510 Protein phosphatase
2C
Toxoplasma gondii ME49 protein phosphatase 2C, putative 95%
21 7894761 TGME49_061750 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 98%
22 7900407 TGME49_078450 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 95%
23 7897848 TGME49_095620 zinc finger (CCCH
type)
Toxoplasma gondii ME49 zinc finger (CCCH type) protein, putative 91%
24 7900113 TGME49_035990 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 91%
25 7899268 TGME49_045880 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 88%
26 7893794 TGME49_067740 hypothetical protein Toxoplasma gondiiME49 hypothetical protein 99%
27 7893464 TGME49_071050 surface antigen P22 Toxoplasma gondii strain 14 surface antigen P22 3′ flanking sequence 85%
28 7899477 TGME49_049670 cysteine proteinase Toxoplasma gondii ME49 cysteine proteinase (cp1) mRNA, complete cds 95%
29 AY424892.1 AY424892.1 UDP-N-acetyl-D-
galactosamine
Toxoplasma gondii UDP-N-acetyl-D galactosamine:polypeptide N-
acetylgalactosaminyltransferase T3 gene, complete cds
90%
Amerizadeh et al. BMC Infectious Diseases 2013, 13:287 Page 8 of 12
http://www.biomedcentral.com/1471-2334/13/287
Meanwhile, sequences of DNA chromosome Ιb were
detected by IgM whereby three sequences which code a
dynamic-like protein, a hypothetical protein and cyclin-N
terminal domain showed increased level of mRNA expres-
sion of in-vivo grown over in-vitro grown T. gondii. Be-
sides, a high increase in the mRNA expression levels
(60.67 fold change) was observed for DNA chromosome
Ιa sequence that was detected by IgG. Comparative studies
between the chromosome genomes of T. gondii RH Type
I and ME49 Type II strains revealed polymorphisms at a
frequency of ~1 in 100 bp among all chromosomes except
chromosome Ia (chrIa). Chromosome Ia has the same
gene content and structural elements in both strains and
this suggest that chrIa has monomorphic inheritance com-
pared to the rest of the T. gondii chromosomes for all
three clonal lineages although the biological basis remains
unknown. The unusual monomorphism of chrIa has led
us to the conclusion that genes located on this chromo-
some may allow some fitness advantage [35].
Eleven other genes with more than 10 times fold
changes include nucleoredoxin, protein phosphatase 2C,
sterol regulatory protein, surface antigen P22 3’ flanking
sequence [SRS34A (= SAG2A, P22)] and six ORF coding
hypothetical proteins. We were most intrigued by the
observation of a very high expression level for one of the
up-regulated genes detected by IgG, with in-vivo over
in-vitro fold change of 499.86. Unfortunately the function
Table 5 Relative mRNA expression levels of T.gondii






Protein encoded by gene
1 7895406 0.86





7 7893824 53.81 sterol-regulatory element binding
protein site
8 7899621 8.6
9 7901413 35.75 microneme
10 7894150 25.28 hypothetical protein
11 7895338 179.76 hypothetical protein









21 AY707938.1 27.28 SRS34A
22 7894324 32.89 hypothetical protein







Table 6 Relative mRNA expression levels of T.gondii
IVIAT-identified genes detected by IgG using 2-ΔΔCt
method
No GenBank ID Fold
change













12 AM055942.3 60.97 hypothetical protein
13 7894058 0.01
14 7893896 0.05
15 7899266 499.86 hypothetical protein
16 7893521 1
17 7893531 2.84
18 7896164 30.70 nucleoredoxin
19 7896097 2.15
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of the gene is unknown. Nucleoredoxin (NRX) is a novel
gene which encodes a protein similar to ATrx1, a member
of thioredoxins (TRX) family. Nucleoredoxin is highly con-
served in all the kingdoms of living organisms and was
formerly reported to be nuclear and more recently cyto-
solic. It appears to play a role in signal transduction and
may be a redox regulator factor of the nuclear proteins
[36,37].
Protein phosphatase 2C (PP2C) is a Mn2+ or Mg2 -
dependent protein Ser/Thr phosphatase secreted by
rhoptry, a secretory organelle of T. gondii. It was identi-
fied in a proteomic survey of rhoptry proteins (ROPs),
and found to be essential for the invasion process of
apicomplexan parasites [38]. Host cell invasion and mo-
tility in apicomplexa protozoa occurs through actin
polymerization as the main process. Actin monomers












































Figure 2 Relative gene expression level (in-vivo to in-vitro) for T.gondii genes identified by IVIAT. (A). Genes detected by IgM antibody







Figure 3 Representative results of sensitivity evaluation of
clone which expressed sterol-regulatory element binding
protein site. AS1-AS4: serum from persons with acute
toxoplasmosis. HC: serum from healthy person.
Table 7 Sensitivity and specificity results for three






7898829 330.8 90% (9/10) 70% (7/10) IgM
7893824 53.81 90% (9/10) 50% (5/10) IgM
7895338 179.76 90% (9/10) 40% (4/10) IgM
AM055942.3 60.97 60% (6/10) 60% (6/10) IgG
7899266 499.86 60% (6/10) 70% (7/10) IgG
7896164 30.70 90% (9/10) 60% (6/10) IgG
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toxofilins and its activities in-vitro and in-vivo are
dependent on phosphorylation of this protein. Recently
a type 2C phosphatase has been reported to be involved
in toxifilin phosphorylation and activity [39].
Sterol regulatory element-binding proteins (SREBPs)
were found to be one of the three most up-regulated se-
quences detected by IgM in this study. SREBPs are
basic-helix-loop-helix leucine zipper class of transcrip-
tion factors which are specific for fatty acid and choles-
terol synthesis. When the level of sterols is low, SREBPs
are cleaved to a water soluble N-terminal domain which
is then translocated to the nucleus [40].
SRS34A (= SAG2A, P22), is a plasma membrane gene of
T. gondii found during and after tachyzoite invasion. SAG
family of proteins which cover the surface of T. gondii
bradyzoites and tachyzoites comprise five main members
i.e. SAG1 (P30 kDa), SAG2 (P22 kDa), SAG3 (P43 kDa),
SAG4 (P23 kDa) and SAG5 (P35 kDa) [41,42]. SAG1 and
SAG2A are immunodominant within the superfamily and
induce a high antibody response in early infection. The
increased mRNA expression level of SRS34A (SAG2A)
which has been detected by IgM in this study is in agree-
ment with other studies which reported that tachyzoite
surface is dominated by SAG1, SAG2A, SAG3, SRS1,
SRS2 and SRS3 and have been shown to be involved in at-
tachment and invasion necessary for early acute T. gondii
infection [43].
Conclusion
This study identified several T. gondii genes with up-
regulated expression in-vivo as compared to in-vitro. Fur-
ther studies including stage-specific expression and local-
isation studies on the highly up-regulated genes and the
corresponding proteins, in particular the hypothetical pro-
teins, should be performed. This may help to increase our
understanding of the disease pathogenesis and asses their
usefulness as potential vaccine candidates.
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